Transcription factor EB enhances autophagy and ameliorates palmitate-induced insulin resistance at least partly via upregulating AMPK activity in skeletal muscle cells

Clin Exp Pharmacol Physiol. 2022 Feb;49(2):302-310. doi: 10.1111/1440-1681.13600. Epub 2021 Oct 21.

Abstract

This study aimed to elucidate the role of transcription factor EB (TFEB) in protecting C2C12 myotubes against palmitate (PA)-induced insulin resistance (IR) and explored its mechanism associated with autophagy. PA treatment significantly decreased insulin sensitivity in myotubes and downregulated TFEB protein expression. TFEB overexpression significantly reversed the PA-suppressed glucose transporter 4 (GLUT4) protein expression and improved intracellular glucose uptake and consumption, and also alleviated the decrease of autophagy markers induced by PA. The effect of TFEB overexpression on GLUT4 was also abolished by the autophagy inhibitor 3-MA. In addition, AMPKɑ2-DN inhibited or abolished the effects of TFEB overexpression on upregulation of GLUT4 and PA-induced decrease of autophagy marker expressions. Taken together, our data demonstrated that upregulation of TFEB improved PA-induced IR in C2C12 myotubes by enhancing autophagy and upregulating AMPK activity. TFEB, as a critical regulator of glucose homeostasis in skeletal muscle cells, may be a potential therapeutic target for IR and Type 2 diabetes.

Keywords: AMPK; C2C12 myotubes; TFEB; autophagy; insulin resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Autophagy
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • Diabetes Mellitus, Type 2* / metabolism
  • Humans
  • Insulin Resistance*
  • Muscle Fibers, Skeletal
  • Muscle, Skeletal / metabolism
  • Palmitates / pharmacology

Substances

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • Palmitates
  • TFEB protein, human
  • AMP-Activated Protein Kinases